75,768 Shares in Mineralys Therapeutics, Inc. $MLYS Purchased by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP bought a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) during the third quarter, Holdings Channel reports. The fund bought 75,768 shares of the company’s stock, valued at approximately $2,873,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Smartleaf Asset Management LLC increased its holdings in shares of Mineralys Therapeutics by 198.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock worth $40,000 after buying an additional 676 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Mineralys Therapeutics by 42.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock valued at $54,000 after acquiring an additional 1,197 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Mineralys Therapeutics by 14,091.3% in the third quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company’s stock valued at $124,000 after acquiring an additional 3,241 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its position in Mineralys Therapeutics by 29.4% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,234 shares of the company’s stock worth $125,000 after acquiring an additional 2,098 shares during the period. Finally, ProShare Advisors LLC purchased a new position in Mineralys Therapeutics in the second quarter worth approximately $141,000. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Mineralys Therapeutics Stock Up 3.4%

Mineralys Therapeutics stock opened at $24.07 on Friday. The firm has a market cap of $1.98 billion, a PE ratio of -10.16 and a beta of 0.57. Mineralys Therapeutics, Inc. has a 52-week low of $10.44 and a 52-week high of $47.65. The company’s 50 day moving average is $29.43 and its two-hundred day moving average is $35.73.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. On average, equities research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, insider David Malcom Rodman sold 192,715 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $35.02, for a total transaction of $6,748,879.30. Following the sale, the insider owned 61,804 shares in the company, valued at $2,164,376.08. This represents a 75.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Adam Scott Levy sold 10,758 shares of Mineralys Therapeutics stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $32.14, for a total value of $345,762.12. Following the completion of the transaction, the chief financial officer owned 8,638 shares of the company’s stock, valued at $277,625.32. The trade was a 55.47% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 363,325 shares of company stock worth $12,298,347. Company insiders own 25.56% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Jefferies Financial Group restated a “hold” rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a research report on Friday, March 13th. Stifel Nicolaus increased their price target on Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Wall Street Zen raised Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. HC Wainwright set a $56.00 price objective on shares of Mineralys Therapeutics and gave the company a “buy” rating in a report on Tuesday, March 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $49.14.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.